- PMID: 33162770
- PMCID: PMC7605020
- DOI: 10.31887/DCNS.2020.22.3/pfadda
Abstract
Mental disorders represent a significant public health burden worldwide due to their high prevalence, chronically disabling nature, and substantial impact on quality of life. Despite growing knowledge of the pathological mechanisms that underlie the development of these disorders, a high percentage of patients do not respond to first-line clinical treatments; thus, there is a strong need for alternative therapeutic approaches. During the past half-century, after the identification of the endocannabinoid system and its role in multiple physiological processes, both natural and synthetic cannabinoids have attracted considerable interest as putative medications in pathological conditions such as, but not exclusive to, mental disorders. Here, we provide a summary of cannabinoid effects in support of possible therapeutic applications for major depression, bipolar disorder, anxiety, posttraumatic stress disorder, and schizophrenia. Considering this evidence, highlighted benefits and risks of cannabinoid use in the management of these illnesses require further experimental study. .
Keywords: anxiety, cannabinoid, cannabis, depression, mental disorders, pharmacotherapy, psychosis
© 2020, AICHServier GroupCopyright © 2020 AICH Servier Group. All rights reserved.
Similar articles
-
Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.Lancet Psychiatry. 2019 Dec;6(12):995-1010. doi: 10.1016/S2215-0366(19)30401-8. Epub 2019 Oct 28.PMID: 31672337
-
Right care, first time: a highly personalised and measurement-based care model to manage youth mental health.Med J Aust. 2019 Nov;211 Suppl 9:S3-S46. doi: 10.5694/mja2.50383.PMID: 31679171
-
Medical Use of Cannabinoids.Drugs. 2018 Nov;78(16):1665-1703. doi: 10.1007/s40265-018-0996-1.PMID: 30374797 Review.
-
Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder.Neuropsychopharmacology. 2018 Jan;43(1):80-102. doi: 10.1038/npp.2017.162. Epub 2017 Jul 26.PMID: 28745306 Free PMC article. Review.
-
Cannabinoids for Treatment of MS Symptoms: State of the Evidence.Curr Neurol Neurosci Rep. 2018 Jun 19;18(8):50. doi: 10.1007/s11910-018-0859-x.PMID: 29923025 Review.
References
-
- Kranaster L, Hoyer C, Aksay SS, et al Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: a preliminary prospective study. Eur Arch Psychiatry Clin Neurosci. 2017;267(8):781–786. – PubMed
-
- Hungund BL, Vinod KY, Kassir SA, et al Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgS binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry. 2004;9(2):184–190. – PubMed